{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:07:13Z","timestamp":1791925633546,"version":"4.3.4"},"reference-count":51,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2019,10,15]]},"DOI":"10.3233\/jad-190626","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T13:28:13Z","timestamp":1567171693000},"page":"1099-1103","source":"Crossref","is-referenced-by-count":6,"title":["Is Combining an Anticholinergic with a Cholinesterase Inhibitor a Good Strategy for High-Level CNS Cholinesterase Inhibition?"],"prefix":"10.1177","volume":"71","author":[{"given":"Donald E.","family":"Moss","sequence":"first","affiliation":[{"name":"Department of Psychology, University of Texas at El Paso, El Paso, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-190626_ref1","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.3233\/JAD-190626_ref2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1176\/appi.ajp.162.4.676","article-title":"Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer\u2019s disease?","volume":"162","author":"Hashimoto","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JAD-190626_ref3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000358510","article-title":"The potentially protective effect of donepezil in Alzheimer\u2019s disease","volume":"38","author":"Ishiwata","year":"2014","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-190626_ref4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.mri.2016.04.025","article-title":"Effects of donepezil on brain morphometric and metabolic changes in patients with Alzheimer\u2019s disease: A DARTEL-based VBM and1H-MRS","volume":"34","author":"Moon","year":"2016","journal-title":"Magn Reson Imaging"},{"key":"10.3233\/JAD-190626_ref5","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1176\/appi.ajp.160.11.2003","article-title":"Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer\u2019s disease","volume":"160","author":"Krishnan","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JAD-190626_ref6","doi-asserted-by":"crossref","first-page":"e1631","DOI":"10.4088\/JCP.15m10413","article-title":"Reduced regional cortical thickness rate of change in donepezil-treated subjects with suspected prodromal Alzheimer\u2019s disease","volume":"77","author":"Cavedo","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"10.3233\/JAD-190626_ref7","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jalz.2014.10.003","article-title":"Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer\u2019s disease","volume":"11","author":"Dubois","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-190626_ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-09780-3","article-title":"Reduced basal forebrain atrophy progression in a randomized donepezil trial in prodromal Alzheimer\u2019s disease","volume":"7","author":"Cavedo","year":"2017","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-190626_ref9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3233\/JAD-142268","article-title":"Understanding the benefits and detrimental effects of donepezil and rivastigmine to improve their therapeutic value","volume":"44","author":"Lane","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190626_ref10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: Few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-190626_ref11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00023210-200115050-00004","article-title":"Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer\u2019s disease","volume":"15","author":"Imbimbo","year":"2001","journal-title":"CNS Drugs"},{"key":"10.3233\/JAD-190626_ref12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2165\/00003088-200241100-00003","article-title":"Clinical pharmacokinetics: Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors","volume":"41","author":"Jann","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.3233\/JAD-190626_ref13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H","article-title":"Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex","volume":"48","author":"Kuhl","year":"2000","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-190626_ref14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/jnnp.2004.038729","article-title":"Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzeimer\u2019s disease","volume":"7","author":"Bohnen","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-190626_ref15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/WNF.0b013e3181c71be9","article-title":"Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer disease using positron emission tomography","volume":"33","author":"Ota","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.3233\/JAD-190626_ref16","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00004714-200212000-00012","article-title":"Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer\u2019s disease","volume":"22","author":"Kaasinen","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.3233\/JAD-190626_ref17","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.neurobiolaging.2007.02.020","article-title":"PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD","volume":"29","author":"Kadir","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-190626_ref18","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3233\/JAD-160733","article-title":"Cholinesterase inhibitor therapy in Alzheimer\u2019s disease: The limits and tolerability of irreversible CNS-selective acetylcholinesterase inhibition in primates","volume":"55","author":"Moss","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190626_ref19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s13311-016-0511-x","article-title":"Donepezil plus solifenacin (CPC-201) treatment for Alzheimer\u2019s disease","volume":"14","author":"Chase","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JAD-190626_ref21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00002093-199903000-00003","article-title":"Methanesulfonyl fluoride (MSF): A double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type","volume":"13","author":"Moss","year":"1999","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-190626_ref22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2125.2011.03961.x","article-title":"A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder","volume":"72","author":"Callegari","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.3233\/JAD-190626_ref23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5213\/inj.2012.16.3.107","article-title":"Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding","volume":"16","author":"Yamada","year":"2012","journal-title":"Int Neurourol J"},{"key":"10.3233\/JAD-190626_ref24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1254\/jphs.09R14FM","article-title":"The forefront for novel therapeutic agents based on in vivo the pathophysiology of lower urinary tract dysfuntion: Bladder selectivity based ondrug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder","volume":"112","author":"Yoshida","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"10.3233\/JAD-190626_ref25","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1124\/jpet.108.136390","article-title":"In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment","volume":"325","author":"Maruyama","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JAD-190626_ref26","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1532-5415.2011.03473.x","article-title":"Systematic review and meta-analysis: Do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?","volume":"59","author":"Paquette","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-190626_ref27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.archger.2016.11.006","article-title":"Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis","volume":"69","author":"Vouri","year":"2017","journal-title":"Arch Gerontol Geriatr"},{"key":"10.3233\/JAD-190626_ref28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.10639","article-title":"Increased Alzheimer pathology in Parkinson\u2019s disease related to antimuscarinic drugs","volume":"54","author":"Perry","year":"2003","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-190626_ref29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: A prospective cohort study","volume":"75","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.3233\/JAD-190626_ref30","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/archinternmed.2009.229","article-title":"Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-city study","volume":"169","author":"Carri\u00e8re","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.3233\/JAD-190626_ref31","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults","volume":"73","author":"Risacher","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-190626_ref32","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1532-5415.2011.03491.x","article-title":"Anticholinergic medication use and cognitive impairment in the older population: The medical research council cognitive function and ageing study","volume":"59","author":"Fox","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-190626_ref33","doi-asserted-by":"crossref","first-page":"k1315","DOI":"10.1136\/bmj.k1315","article-title":"Anticholinergic drugs and risk of mementia: Case-control study","volume":"360","author":"Richardson","year":"2018","journal-title":"Br Med J"},{"key":"10.3233\/JAD-190626_ref34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bcp.13734","article-title":"Anticholinergic exposure and cognitive decline in older adults: Effect of anticholinergic exposure definitions in a 3-year analysis of the multidomain Alzheimer preventive trial (MAPT) study","volume":"85","author":"Andre","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.3233\/JAD-190626_ref35","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.0677"},{"key":"10.3233\/JAD-190626_ref36","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.neurobiolaging.2015.07.009","article-title":"Disruption of cholinergic neurotransmission exacerbates A\u03b2-related cognitive impairment in preclinical Alzheimer\u2019s disease","volume":"36","author":"Lim","year":"2015","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-190626_ref37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/jnr.20060","article-title":"Differential regulation of neurotrophin expression in basal forebrain astrocytes by neuronal signals","volume":"76","author":"Wu","year":"2004","journal-title":"J Neurosci Res"},{"key":"10.3233\/JAD-190626_ref38","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1073\/pnas.0510645103","article-title":"Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade","volume":"103","author":"Bruno","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-190626_ref39","doi-asserted-by":"crossref","first-page":"10037","DOI":"10.1073\/pnas.88.22.10037","article-title":"Interplay between gluatmate and gamma-aminobutyric-acid transmitter systems in the physiological regulation of brain-derived neurotrophic factor and nerve growth factor synthesis in hippocampal neurons","volume":"88","author":"Zafra","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-190626_ref40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1006\/mcne.1996.0014","article-title":"Localization of cellular storage compartments and sites of constitutive and activity-dependent release of nerve growth factor (NGF) in primary cultures of hippocampal neurons","volume":"7","author":"Bl\u00f6chl","year":"1996","journal-title":"Mol Cell Neurosci"},{"key":"10.3233\/JAD-190626_ref41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0006-3223(00)01047-7","article-title":"Is there nicotinic modulation of nerve growth factor? Implications for cholinergic therapies in Alzheimer\u2019s disease","volume":"49","author":"Rattray","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.3233\/JAD-190626_ref42","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12031-009-9238-z","article-title":"Cholinergic involvement in Alzheimer\u2019s disease. A link with NGF maturation and degradation","volume":"40","author":"Cuello","year":"2010","journal-title":"J Mol Neurosci"},{"key":"10.3233\/JAD-190626_ref43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/1567205012666150921100030","article-title":"The NGF metabolic pathway in the CNS and its dysregulation in Down syndrome and Alzheimer\u2019s disease","volume":"13","author":"Iulita","year":"2016","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-190626_ref44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnins.2019.00038","article-title":"Innovative therapy for Alzheimer\u2019s disease-with focus on biodelivery of NGF","volume":"13","author":"Mitra","year":"2019","journal-title":"Front Neurosci"},{"key":"10.3233\/JAD-190626_ref45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fncel.2017.00068","article-title":"Impaired NGF\/TrkA signaling causes early AD-linked presynaptic dysfunction in cholinergic primary neurons","volume":"11","author":"Latina","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"10.3233\/JAD-190626_ref46","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1586\/14737175.8.11.1703","article-title":"Cholinergic system during the progression of Alzheimer\u2019s disease: Therapeutic implications","volume":"8","author":"Mufson","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.3233\/JAD-190626_ref47","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3233\/JAD-141068","article-title":"Brain changes in Alzheimer\u2019s disease patients with implanted encapsulated cells releasing nerve growth factor","volume":"43","author":"Ferreira","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190626_ref48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13195-016-0195-9","article-title":"Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer\u2019s disease patients: Application of a second-generation encapsulated cell biodelivery device","volume":"8","author":"Eyjolfsdottir","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-190626_ref49","doi-asserted-by":"crossref","first-page":"e0209250","DOI":"10.1371\/journal.pone.0209250","article-title":"Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors","volume":"13","author":"Terada","year":"2018","journal-title":"PLoS One"},{"key":"10.3233\/JAD-190626_ref50","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.pnpbp.2008.06.011","article-title":"Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: Role of sigma-1 receptors and IP3 receptors","volume":"32","author":"Ishima","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.3233\/JAD-190626_ref51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ucl.2006.06.006","article-title":"Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder","volume":"33","author":"Staskin","year":"2006","journal-title":"Urol Clin North Am"},{"key":"10.3233\/JAD-190626_ref52","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1742-1241.2010.02433.x","article-title":"Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder","volume":"64","author":"Staskin","year":"2010","journal-title":"Int J Clin Pract"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-190626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:06:46Z","timestamp":1777370806000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-190626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":51,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jad-190626","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]}}}